Literature DB >> 26014952

RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.

Julien M Buyck1, Frédéric Peyrusson1, Paul M Tulkens1, Françoise Van Bambeke2.   

Abstract

The pyrrolocytosine RX-P873, a new broad-spectrum antibiotic in preclinical development, inhibits protein synthesis at the translation step. The aims of this work were to study RX-P873's ability to accumulate in eukaryotic cells, together with its activity against extracellular and intracellular forms of infection by Staphylococcus aureus and Pseudomonas aeruginosa, using a pharmacodynamic approach allowing the determination of maximal relative efficacies (Emax values) and bacteriostatic concentrations (Cs values) on the basis of Hill equations of the concentration-response curves. RX-P873's apparent concentration in human THP-1 monocytes was about 6-fold higher than the extracellular one. In broth, MICs ranged from 0.125 to 0.5 mg/liter (S. aureus) and 2 to 8 mg/liter (P. aeruginosa), with no significant shift in these values against strains resistant to currently used antibiotics being noted. In concentration-dependent experiments, the pharmacodynamic profile of RX-P873 was not influenced by the resistance phenotype of the strains. Emax values (expressed as the decrease in the number of CFU from that in the initial inoculum) against S. aureus and P. aeruginosa reached more than 4 log units and 5 log units in broth, respectively, and 0.7 log unit and 2.7 log units in infected THP-1 cells, respectively, after 24 h. Cs values remained close to the MIC in all cases, making RX-P873 more potent than antibiotics to which the strains were resistant (moxifloxacin, vancomycin, and daptomycin for S. aureus; ciprofloxacin and ceftazidime for P. aeruginosa). Kill curves in broth showed that RX-P873 was more rapidly bactericidal against P. aeruginosa than against S. aureus. Taken together, these data suggest that RX-P873 may constitute a useful alternative for infections involving intracellular bacteria, especially Gram-negative species.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26014952      PMCID: PMC4505283          DOI: 10.1128/AAC.00428-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.

Authors:  Mickaël Riou; Sylviane Carbonnelle; Laëtitia Avrain; Narcisa Mesaros; Jean-Paul Pirnay; Florence Bilocq; Daniel De Vos; Anne Simon; Denis Piérard; Frédérique Jacobs; Anne Dediste; Paul M Tulkens; Françoise Van Bambeke; Youri Glupczynski
Journal:  Int J Antimicrob Agents       Date:  2010-12       Impact factor: 5.283

2.  Antibiotic-resistant bugs in the 21st century--a clinical super-challenge.

Authors:  Cesar A Arias; Barbara E Murray
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

3.  Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells.

Authors:  Raquel Garcia-Medina; W Michael Dunne; Pradeep K Singh; Steven L Brody
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.

Authors:  Maritza Barcia-Macay; Sandrine Lemaire; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  J Antimicrob Chemother       Date:  2006-10-24       Impact factor: 5.790

Review 5.  Commentary. Lysosomotropic agents.

Authors:  C de Duve; T de Barsy; B Poole; A Trouet; P Tulkens; F Van Hoof
Journal:  Biochem Pharmacol       Date:  1974-09-15       Impact factor: 5.858

6.  Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.

Authors:  Pierre Baudoux; Sandrine Lemaire; Olivier Denis; Paul M Tulkens; Françoise Van Bambeke; Youri Glupczynski
Journal:  J Antimicrob Chemother       Date:  2010-04-08       Impact factor: 5.790

7.  Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila.

Authors:  Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens
Journal:  Int J Antimicrob Agents       Date:  2011-05-18       Impact factor: 5.283

8.  Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains.

Authors:  Hoang Anh Nguyen; Olivier Denis; Anne Vergison; Anne Theunis; Paul M Tulkens; Marc J Struelens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

9.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

Review 10.  Intracellular Staphylococcus aureus: live-in and let die.

Authors:  Martin Fraunholz; Bhanu Sinha
Journal:  Front Cell Infect Microbiol       Date:  2012-04-24       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.